1-8 of 8
Elisa Cerri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Frequency of Tumor Lysis Syndrome Among Patients Diagnosed with Hematologic Malignancies

Sudeep Karve, PhD, Robert Diegidio, MS, Dongmu Zhang, PhD, Wendy Sebby, MPH, Elisa Cerri, MD, Tanja Rosenberg, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2311.
https://doi.org/10.1182/blood-2018-99-117154
Published: 2018
Journal Articles

Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia

John F Seymour, Matthew S. Davids, Andrew W. Roberts, Michael Hallek, William G. Wierda, MD PhD, Peter Hillmen, John F. Gerecitano, Elisa Cerri, Jalaja Potluri, Su Young Kim, Todd Busman, Maria Verdugo, Rod A. Humerickhouse, MD, Andrea Best, Monali Desai, Stephan Stilgenbauer
Journal: Blood
Blood (2016) 128 (22): 4395.
https://doi.org/10.1182/blood.V128.22.4395.4395
Published: 2016
Journal Articles

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Stephan Stilgenbauer, MD PhD, Barbara F. Eichhorst, MD, Johannes Schetelig, MD, M.Sc, Steven Coutre, MD, John F. Seymour, MBBS, PhD, Talha Munir, MBBS, MRCP, FRCPath, Soham D. Puvvada, MD, Clemens-Martin Wendtner, MD, Andrew W. Roberts, MBBS, PhD, Wojciech Jurczak, MD, PhD, Stephen Mulligan, MBBS, PhD, FRACP, FRCPA, Sebastian Boettcher, MD, Mehrdad Mobasher, MD, Ming Zhu, PhD, Brenda Chyla, PhD, Maria Verdugo, MD, Sari Heitner Enschede, MD, Elisa Cerri, MD, Rod A. Humerickhouse, MD, PhD, Gary Gordon, MD, PhD, Michael Hallek, MD, William Wierda, MD, PhD
Journal: Blood
Blood (2015) 126 (23): LBA-6.
https://doi.org/10.1182/blood.V126.23.LBA-6.LBA-6
Published: 2015
Journal Articles

Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Andrew W. Roberts, MBBS, PhD, Shuo Ma, MD PhD, Danielle M. Brander, MD, Thomas J. Kipps, MD PhD, Jacqueline C. Barrientos, MD, Matthew S. Davids, MD, Mary Ann Anderson, PhD, Constantine Tam, MD, Tanita Mason-Bright, Nikita K. Rudersdorf, Lori Gressick, BS, Jianning Yang, PhD, Wijith Munasinghe, PhD, Ming Zhu, PhD, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD PhD, John F Seymour, MBBS, FRACP, PhD
Journal: Blood
Blood (2014) 124 (21): 325.
https://doi.org/10.1182/blood.V124.21.325.325
Published: 2014
Journal Articles

The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients

Matthew S. Davids, MD, John F. Seymour, MBBS, FRACP, PhD, John F. Gerecitano, MD, PhD, Brad S. Kahl, MD, John M. Pagel, MD, PhD, William G. Wierda, MD, PhD, Mary-Ann Anderson, Nikita K. Rudersdorf, Lori A. Gressick, BS, Nicholas P. Montalvo, MBA, CCRP, Jianning Yang, PhD, Todd A. Busman, MS, Martin Dunbar, DRPH, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2013) 122 (21): 1789.
https://doi.org/10.1182/blood.V122.21.1789.1789
Published: 2013
Journal Articles

Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

John F. Seymour, MBBS, FRACP, PhD, Matthew S. Davids, MD, John M. Pagel, MD, PhD, Brad S. Kahl, MD, William G. Wierda, MD, Thomas P. Miller, MD, John F. Gerecitano, MD, PhD, Thomas J. Kipps, MD, PhD, Mary-Ann Anderson, David C.S. Huang, MB, BS, MRCP, PhD, Nikita K. Rudersdorf, Lori A. Gressick, BS, Nicholas P. Montalvo, MBA, CCRP, Jianning Yang, PhD, Todd A. Busman, MS, Martin Dunbar, DRPH, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2013) 122 (21): 872.
https://doi.org/10.1182/blood.V122.21.872.872
Published: 2013
Journal Articles

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study

John F. Seymour, MBBS FRACP, Matthew S. Davids, MD, Mary Ann Anderson, PhD, Thomas J. Kipps, MD, PhD, William G. Wierda, MD, PhD, John M. Pagel, MD, PhD, Brad S. Kahl, M.D., Thomas P. Miller, MD, David E. Darden, MS, Cathy E. Nolan, BS, Lori A. Gressick, BS, Hao Xiong, PhD, David C.S. Huang, MB BS MRCP PhD, Brenda J. Chyla, PhD, Todd A. Busman, MS, Alison M. Graham, PhD, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2012) 120 (21): 3923.
https://doi.org/10.1182/blood.V120.21.3923.3923
Published: 2012
Journal Articles

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

Matthew S. Davids, MD, Andrew W. Roberts, MD, PhD, Mary Ann Anderson, PhD, John M. Pagel, MD, PhD, Brad S. Kahl, M.D., John F. Gerecitano, MD, PhD, David E. Darden, MS, Cathy E. Nolan, BS, Lori A. Gressick, BS, Jianning Yang, PhD, Brenda J. Chyla, PhD, Todd A. Busman, MS, Alison M. Graham, PhD, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD, John F. Seymour, MBBS FRACP
Journal: Blood
Blood (2012) 120 (21): 304.
https://doi.org/10.1182/blood.V120.21.304.304
Published: 2012